- Petrelintide achieved up to 10.7% mean weight reduction at week 42 versus 1.7% with placebo.
- The ZUPREME-1 trial involved 493 participants with a mean BMI of 37 kg/m².
- Phase III trial designs will be informed by final ZUPREME-1 data, expected in 2026.
- Genentech and Roche collaborate with Zealand to develop petrelintide.
Trial Results
Petrelintide, an investigational amylin analog, demonstrated significant weight loss in the Phase II ZUPREME-1 trial. Participants achieved up to 10.7% mean body weight reduction at week 42 compared to 1.7% with placebo. The trial involved 493 individuals with a mean BMI of 37 kg/m², and the weight loss was sustained through week 42.
Tolerability and Safety
Petrelintide showed a favorable tolerability profile, comparable to placebo, with no unexpected safety signals. The treatment discontinuation rate due to adverse events was 4.8% for petrelintide versus 4.9% for placebo. Gastrointestinal-related adverse events were mostly mild, with lower vomiting rates in the petrelintide group compared to placebo.
Future Developments
The final ZUPREME-1 data, including a nine-week safety follow-up, will guide Phase III trial designs. Results from the second Phase II trial, ZUPREME-2, focusing on individuals with obesity or overweight and type 2 diabetes, are expected in the second half of 2026. A Phase II trial exploring the combination of petrelintide and CT-388 is planned for later in 2026.
Collaboration and Market Context
Genentech and Roche have partnered with Zealand to co-develop and co-commercialize petrelintide. Obesity is a major global health issue, projected to affect over four billion people by 2035, driven by genetic, behavioral, and socioeconomic factors. This trend increases the burden on healthcare systems due to associated comorbidities and reduced quality of life.
